Cargando…

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer

Human epidermal growth factor receptor 3 (HER3) expression in lung and breast cancers has a negative impact on survival. Patritumab, a human anti‐HER3 mAb, has shown anticancer activity in preclinical models. This study examined the safety and pharmacokinetics of patritumab in combination with trast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukai, Hirofumi, Saeki, Toshiaki, Aogi, Kenjiro, Naito, Yoichi, Matsubara, Nobuaki, Shigekawa, Takashi, Ueda, Shigeto, Takashima, Seiki, Hara, Fumikata, Yamashita, Tomonari, Ohwada, Shoichi, Sasaki, Yasutsuna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084669/ https://www.ncbi.nlm.nih.gov/pubmed/27452985 http://dx.doi.org/10.1111/cas.13017

Ejemplares similares

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
por: Mukai, Hirofumi, et al.
Publicado: (2014)

Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer
por: TAKASHIMA, SEIKI, et al.
Publicado: (2015)

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
por: Saeki, Toshiaki, et al.
Publicado: (2016)

Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
por: Hara, Fumikata, et al.
Publicado: (2010)

Metastatic Breast Cancer to the Stomach Resembling Early Gastric Cancer
por: Hara, Fumikata, et al.
Publicado: (2010)

A Case of Multiple Liver Metastases after Surgery in Elderly HER2-Positive Breast Cancer in Which Anastrozole + Trastuzumab Was Ineffective but T-DM1 Was Effective
por: Shidahara, Tomohiro, et al.
Publicado: (2021)

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors
por: Lu, Yasong, et al.
Publicado: (2022)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
por: Tsurutani, Junji, et al.
Publicado: (2020)

Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
por: Taira, Naruto, et al.
Publicado: (2021)

Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
por: Taira, Naruto, et al.
Publicado: (2021)

Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
por: Shimizu, Toshio, et al.
Publicado: (2017)

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer
por: Inoue, Kenichi, et al.
Publicado: (2015)

Prospective study of hair recovery after (neo)adjuvant chemotherapy with scalp cooling in Japanese breast cancer patients
por: Ohsumi, Shozo, et al.
Publicado: (2021)

Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study
por: Watanabe, Toru, et al.
Publicado: (2017)

Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety
por: Sugitani, Ikuko, et al.
Publicado: (2017)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer
por: Tamura, Kenji, et al.
Publicado: (2017)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
por: Ueda, Shigeto, et al.
Publicado: (2016)

Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors
por: Mukai, Hirofumi, et al.
Publicado: (2016)

Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers
por: Takaoka, Megumi, et al.
Publicado: (2021)

Delayed Paclitaxel-Trastuzumab-Induced Interstitial Pneumonitis in Breast Cancer
por: Abulkhair, Omalkhair, et al.
Publicado: (2011)

Burst of Corneal Dendritic Cells during Trastuzumab and Paclitaxel Treatment
por: Sterenczak, Katharina A., et al.
Publicado: (2021)

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
por: Sella, Tal, et al.
Publicado: (2022)

The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis
por: Funasaka, Chikako, et al.
Publicado: (2021)

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
por: Jänne, Pasi A., et al.
Publicado: (2022)

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404
por: Shien, Tadahiko, et al.
Publicado: (2014)

A Rare Case of Paclitaxel and/or Trastuzumab Induced Acute Hepatic Necrosis
por: Mandaliya, Hiren, et al.
Publicado: (2015)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Correction: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
Publicado: (2022)

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
por: Pegram, Mark D., et al.
Publicado: (2018)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3‐Hour Infusion of Paclitaxel
por: Minami, Hironobu, et al.
Publicado: (2001)

Genomic Profiling Shows Increased Glucose Metabolism in Luminal B Breast Cancer
por: Ueda, Shigeto, et al.
Publicado: (2013)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
por: Patel, Tejal A., et al.
Publicado: (2019)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
por: Tokunaga, Eriko, et al.
Publicado: (2021)

Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study
por: Shigekawa, Takashi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hftni3jdqjj4id34mnkum267m1